Related Experiment Video

Updated: Mar 23, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K

Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond

Thomas J Borody1, Debra Peattie2, Scott W Mitchell3

  • 1Centre for Digestive Diseases, 1/229 Great North Rd, Five Dock, NSW 2046 Australia. thomas.borody@cdd.com.au.

Antibiotics (Basel, Switzerland)
|March 31, 2016
PubMed

Insights

Fecal Microbiota Transplantation (FMT) effectively cures Clostridium difficile infection (CDI) across diverse patient groups. Future research and oral FMT formulations may improve outcomes for other gastrointestinal diseases.

Area of Science:

  • Gastroenterology
  • Microbiome Research
  • Clinical Therapeutics

Background:

  • Fecal Microbiota Transplantation (FMT) has evolved significantly, demonstrating high efficacy and safety in treating Clostridium difficile infection (CDI).
  • FMT success in CDI is consistent across various patient demographics and health statuses, including those with Inflammatory Bowel Disease (IBD).
  • However, FMT has shown limited success in treating non-CDI gastrointestinal diseases like IBD.

Purpose of the Study:

  • To review the established success of FMT in CDI treatment.
  • To highlight the limitations of FMT in treating other gastrointestinal conditions.
  • To propose future research directions for optimizing FMT in non-CDI diseases.

Main Methods:

  • Review of existing literature on Fecal Microbiota Transplantation (FMT) for Clostridium difficile infection (CDI) and other gastrointestinal (GI) diseases.
  • Analysis of FMT success rates across different patient populations and disease states.
  • Discussion of potential improvements and future research needs, including innovative Randomized Controlled Trials (RCTs) and novel delivery methods.

Main Results:

  • FMT is a highly effective cure for Clostridium difficile infection (CDI) with minimal adverse effects in all patient types.
  • FMT generally fails to cure other gastrointestinal diseases, such as Inflammatory Bowel Disease (IBD) without concurrent CDI.
  • Oral delivery of lyophilized fecal microbiota offers a simplified and potentially more effective approach for both CDI and non-CDI treatments.

Conclusions:

  • Fecal Microbiota Transplantation (FMT) is a proven therapy for Clostridium difficile infection (CDI).
  • Further innovative research, including well-designed Randomized Controlled Trials (RCTs), is necessary to explore FMT's efficacy in other gastrointestinal diseases.
  • The development of orally administered FMT products promises to enhance treatment convenience and effectiveness for a broader range of conditions.
Keywords:
Clostridium difficileCrohn’sFecal microbiota transplantationIBDcolitisinflammatory bowel diseaseirritable bowel

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K
Murine Fecal Isolation and Microbiota Transplantation07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.9K

Related Concept Videos

Microbiota of the Large Intestine01:27

Microbiota of the Large Intestine

The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
3
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
11
Introduction to the Human Microbiota01:22

Introduction to the Human Microbiota

Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity,...
29
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
855
What is Monogastric Digestion?01:50

What is Monogastric Digestion?

The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
78.5K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K